Changes in T cell subsets identify responders to FcR non-binding anti-CD3 mAb (teplizumab) in patients with Type 1 diabetes

The mechanisms whereby immune therapies affect progression of Type 1 diabetes (T1D) are not well understood. Teplizumab, an FcR non-binding anti-CD3 mAb, has shown efficacy in multiple randomized clinical trials. We previously reported an increase in the frequency of circulating CD8+ central memory...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Eur J Immunol
Main Authors: Tooley, James E, Vudattu, Nalini, Choi, Jinmyung, Cotsapas, Chris, Devine, Lesley, Raddassi, Khadir, Ehlers, Mario R, McNamara, James G, Harris, Kristina M, Kanaparthi, Sai, Phippard, Deborah, Herold, Kevan C
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4882099/
https://ncbi.nlm.nih.gov/pubmed/26518356
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/eji.201545708
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados